ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0721

Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Abstract Number: 0457

Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening
Abstract Number: 2674

Pulmonary ultrasound findings and their relationship with clinical characteristics and myopathy antibodies in a cohort of patients with myositis
Abstract Number: 0006

QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Abstract Number: 2560

Quality and Accuracy of TikTok Videos on Axial Spondyloarthritis: A Modified DISCERN Analysis
Abstract Number: 0767

Quality of Life in Patients with Rheumatoid Arthritis with Foot and Ankle Involvement
Abstract Number: 2677

Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease
Abstract Number: 0396

Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers
Abstract Number: 1425

Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Abstract Number: 1890

Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021
Abstract Number: 0690

Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease
Abstract Number: 2673

Quantitative 18F-FDG PET/CT analysis reveals new patterns of muscle involvement and prognostic indicators in idiopathic inflammatory myopathies: beyond proximal muscle weakness
Abstract Number: 1256

Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Abstract Number: 1951

Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment
Abstract Number: 1946

Quantitative Imaging Analysis of Chest Computed Tomography in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].